Akademik Veri Yönetim Sistemi
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, cilt.101, sa.8, ss.761-764, 2009 (SCI-Expanded)
The aim of the study was to evaluate the efficacy and tolerability of gemcitabine and uracil-tegafur (LIFT) combination in patients with advanced pancreatic carcinoma, retrospectively. Thirty-one patients, including 27 with metastatic disease, were treated with gemcitabine at a dose of 1000 Mg/m(2) in 30 minutes on days 1 and 8, and oral UFT 300 mg/m(2) on days 1-14, as the first-line regimen in advanced stage. The cycle was repeated every 21 days. A total of 116 cycles of chemotherapy were administered, with a median of 3 cycles per patient (range 1-13). The objective response rate was observed in 6 (19.3%) patients with 1 (3.2%) complete response, and 5 (16.1%) partial responses. The median response duration was 4 (range, 3-14) months. Eight (25.8%) patients had a standard deviation of more than 3 months. Median overall survival was 8 months (95% Cl, 6-10 months) and median time to progression was 4.2 months (95% Cl, 1-6 months). This combination was generally well tolerated. There were no life-threatening side effects. Most common toxicities were of hematologic and gastrointestinal nature. In conclusion, this regimen was well tolerated and seemed to have a moderate activity in the palliative treatment of advanced pancreatic carcinoma.